Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
13
×
fda
13
×
life sciences
national blog main
boston top stories
national top stories
new york blog main
new york top stories
clinical trials
san francisco blog main
biotech
boston
san diego blog main
san diego top stories
san francisco top stories
drugs
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
patisiran
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
akcea therapeutics
cancer
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
onpattro
rna interference
What
medicine
13
×
drug
fda
alnylam
approved
gain
new
rna
rnai
ago
big
bio
cancer
cells
health
interference
making
momentum
oks
patients
pharmaceuticals
post
rest
roundup
second
specifically
time
uses
vote
weight
acquire
advance
afternoon
agreed
alkermes
alnylam’s
anemia
announced
antipsychotic
approval
Language
unset
Current search:
fda
×
" boston blog main "
×
medicine
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine